Eikon Therapeutics, Inc. EIKN
5.17 USD +0.02 (+0.39%)
Regular-session close
5.17 0.00 0.00%
After hours · Nov 18, 4:01 PM ET
5.02 Day range 5.38
4.95 52-week range 17.40
- YTD
- -65.53%
- 1 year
- -65.53%
News
benzinga.com Morgan Stanley Maintains Overweight on Eikon Therapeutics, Lowers Price Target to $30 Morgan Stanley analyst Sean Laaman maintains Eikon Therapeutics (NASDAQ:EIKN) with a Overweight and lowers the price target from $32 to $30.
benzinga.com Eikon Therapeutics Receives FDA Clearance To Proceed For Investigational New Drug Application To Evaluate EIK1006 For Treatment Of Advanced Metastatic Prostate Cancer; Expects Initial Clinical Data From Phase 1/2 Study In H2 2027 Eikon plans to initiate a Phase 1/2 study, ARGATE-001, to evaluate the safety, tolerability and preliminary efficacy of EIK1006 in participants with metastatic androgen-pathway-modulation-resistant…
globenewswire.com Eikon Therapeutics Announces Clearance to Proceed with First-in-Human Phase 1/2 Study for Novel Androgen Receptor Antagonist EIK1006 in Advanced Metastatic Prostate Cancer MILLBRAE, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to…benzinga.com Eikon Therapeutics Q3 EPS $(1.59) Beats $(1.68) Estimate Eikon Therapeutics (NASDAQ:EIKN) reported quarterly losses of $(1.59) per share which beat the analyst consensus estimate of $(1.68) by 5.36 percent. This is a 93.44 percent increase over losses of…
globenewswire.com Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Updates MILLBRAE, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Co-Diagnostics (NASDAQ:CODX) stock moved upwards by 22.4% to $0.39 during Tuesday's pre-market session. The company's market cap stands at $2.8 million. As per the press release, Q3 earnings…
marketbeat.com Eikon Therapeutics Eyes 2027 Melanoma Trial Update, With Key Cancer Data Expected in 2029 Eikon Therapeutics NASDAQ: EIKN expects an interim analysis of its lead melanoma study in the first half of 2027 and estimates that definitive data from that trial and a lung cancer study could be…
seekingalpha.com Eikon Therapeutics, Inc. (EIKN) Presents at JP Morgan Biotech Call Series Transcript Eikon Therapeutics, Inc. (EIKN) Presents at JP Morgan Biotech Call Series Transcript
globenewswire.com Eikon Therapeutics to Participate in Multiple Investor Conferences in November MILLBRAE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to…benzinga.com Eikon Therapeutics Announces EIK1001 Plus Pembrolizumab And Chemotherapy In First-Line, Stage 4 Non-Small Cell Lung Cancer Demonstrates Durable Effect In Combination With Standard-Of-Care, With Tolerability Profile Supportive Of Systemic Administration In An Outpatient Setting EIK1001 Clinical Update:Updated data from the open-label TeLuRide-005 trial evaluating TLR7/8 dual-agonist EIK1001 in combination with both pembrolizumab and histology-appropriate chemotherapy in…
globenewswire.com Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress MILLBRAE, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to…benzinga.com Eikon Therapeutics Presents Initial And Updated Data For EIK1003 And Initial Data For EIK1004 And EIK1005 At ESMO 2026; Initial And Updated Cohort Data From Ongoing Phase 1/2 Study Of EIK1003 Continue To Support Potentially Differentiated Profile Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced…
globenewswire.com Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress MILLBRAE, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to…
globenewswire.com Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress Presentations to cover updates across Eikon's clinical pipeline including: Updated data from TeLuRide-005, an ongoing open-label Phase 2 trial of EIK1001, a TLR7/8 dual-agonist, plus pembrolizumab…
globenewswire.com Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer MILLBRAE, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to…
seekingalpha.com Eikon Therapeutics, Inc. (EIKN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Eikon Therapeutics, Inc. (EIKN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
globenewswire.com Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to…
globenewswire.com Eikon Therapeutics to Participate in Investor Conferences in September 2026 MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to…
marketbeat.com Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004 Eikon Therapeutics NASDAQ: EIKN outlined its development strategy for selective PARP1 inhibitors and its Werner helicase inhibitor during a discussion hosted by Cantor biotech analyst Imogen…
seekingalpha.com Eikon Therapeutics, Inc. (EIKN) Discusses Advances in PARP1 Biology and Next-Generation PARP Inhibitors in Oncology Transcript Eikon Therapeutics, Inc. (EIKN) Discusses Advances in PARP1 Biology and Next-Generation PARP Inhibitors in Oncology Transcript
globenewswire.com Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald Chairman and Chief Executive Officer, Roger M. Perlmutter, M.D., Ph.D., will participate in a key opinion leader (KOL) event on Thursday, August 20, 2026
globenewswire.com Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates MILLBRAE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to…
globenewswire.com Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board MILLBRAE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to…
defenseworld.net Eikon Therapeutics, Inc.’s (NASDAQ:EIKN) Lock-Up Period Will Expire on August 4th Eikon Therapeutics' (NASDAQ: EIKN - Get Free Report) lock-up period will end on Tuesday, August 4th. Eikon Therapeutics had issued 21,177,600 shares in its IPO on February 5th. The total size of the…
globenewswire.com Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer MILLBRAE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to…
globenewswire.com Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress Presentations to cover updates across Eikon's clinical pipeline including: Updated data from TeLuRide-005, an ongoing Phase 2 trial of EIK1001, a TLR7/8 dual agonist, plus pembrolizumab and…
